In trials involving cancers like non‐small cell lung cancer (NSCLC), combining anti‐VEGF therapy with anti‐PD‐L1 inhibitors showed that patients with high VM density experienced a significant reduction in VM formation and improved survival rates, providing a foundation for further exploration of such therapies [118]. This evidence concerns the gene VEGFA and cancer.